Flexion Therapeutics Profile

USD 0.44  1.74%
23.49Last Month High 26.32 
24.79Trading Day  High 25.81 

Flexion Therapeutics exotic insider transaction detected

Flexion Therapeutics Inc insider trading alert for general transaction of common stock by Neil Bodick, Chief Scientific Officer, on November 22, 2017. This event was filed by Flexion Therapeutics Inc with SEC on 2017-11-22. Statement of changes in beneficial ownership - SEC Form 4. Neil Bodick is currently serves as chief medical officer & co-founder of Flexion Therapeutics Inc [view details]   

Flexion Therapeutics Summary

Flexion Therapeutics Inc (FLXN) is traded on NASDAQ General Markets in USA. It is located in MASSACHUSETTS, U.S.A and employs 48 people. Flexion Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 917.87 M. Flexion Therapeutics Inc conducts business under Healthcare sector and is part of Drugs - Generic industry. This company has 37.54 M outstanding shares of which 10.35 M shares are currently shorted by private and institutional investors with about 6.06 trading days to cover. Flexion Therapeut currently holds about 335.1 M in cash with (86.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.93.
Check Flexion Therapeutics Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Gilder Gagnon Howe Co LlcCommon Shares4 M95.8 M
Bank Of New York Mellon CorpCommon Shares2.6 M62.8 M
Susquehanna International Group LlpPut Options323.5 K7.8 M
Susquehanna International Group LlpCall Options286.2 K6.9 M
View Flexion Therapeutics Diagnostics

Selected Flexion Therapeutics Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Flexion Therapeutics Against Markets

Current Ratings  

Flexion Therapeutics 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
< 36% 
Flexion Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of antiinflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameFlexion Therapeutics Inc
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock Stocks Directory
RegionNorth America
Business Address10 Mall Road Suite 301, Burlington, MA 01803, United States
ExchangeNASDAQ General Markets
CIK Number01419600.0
IndustryDrugs - Generic
Contact Number781 305 7777
CurrencyUSD - US Dollar


Flexion Therapeutics Analyst Recommendations
Target PriceAdvice# of Analysts
35.0Strong Buy4Odds
Flexion Therapeutics Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Flexion Therapeutics Analyst Advice  


Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  


Flexion Therapeutics Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.67March 9, 2017
Flexion Therapeutics Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate